Clinical Bulletins

Next Generation Biosimilars

On July 28th, the Food and Drug Administration (FDA) approved Semglee® as the first interchangeable biosimilar insulin product in the United States. Semglee (insulin glargine-yfgn) is indicated to control high blood sugar in adults with Type 2 diabetes and adults and pediatric patients with Type 1 diabetes.

Updated Warning for JAK Inhibitors

On September 1, 2021, the FDA announced required revisions to the Boxed Warning for Xeljanz®/Xeljanz XR® (tofacitinib), Olumiant® (baricitinib), and Rinvoq™ (upadacitnib) to include information about the risks of serious heart-related events, cancer, blood clots, and death.

New Lupus Treatment Approved

On July 30, 2021, the FDA approved SaphneloTM (anifrolumab-fnia) for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy

Potential New Therapy for Alzheimer's Disease

In July at the Alzheimer’s Association International Conference (AAIC), Lilly shared additional data from TRAILBLAZER-ALZ.

Clinical Bulletin

The June 2021 edition of our Clinical Bulletin details advancements in chronic weight management as well as promising results for ulcerative colitis treatment.

Awards and Accolades

AscellaHealth is proud to be recognized as a leading healthcare organization across the nation.We have won multiple awards nationally both within and outside of the healthcare industry.
AscellaHealth award
Soaring 76 award
Philadelphia 100 Forum 2021 award
Inc 5000 award
2021 Most Admired CEO's award
Fast 500 award
Cookie Policy

Read our Privacy Policy to learn more.